Standout Papers

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signal... 2007 2026 2013 2019 3.5k
  1. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling (2007)
    Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Science
  2. PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib (2007)
    Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Cancer Research

Immediate Impact

10 by Nobel laureates 24 from Science/Nature 102 standout
Sub-graph 1 of 15

Citing Papers

Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
Lung cancer
2021 Standout
8 intermediate papers

Works of Kreshnik Zejnullahu being referenced

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
2010
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
and 3 more

Author Peers

Author Last Decade Papers Cites
Kreshnik Zejnullahu 3161 3071 3115 16 5.4k
Youngchul Song 2639 2959 2984 18 5.4k
Alison J. Holmes 3458 2288 3089 16 5.3k
Andrew M. Rogers 2666 2415 2578 21 4.6k
Apurva A. Desai 3973 3863 2426 35 6.7k
Samuel E. DePrimo 2423 2716 2164 39 5.2k
Sean Tracy 5535 3126 5019 19 8.1k
Jeffrey C. Lee 5694 4108 5036 14 9.3k
Andrea Kay 4627 3673 3189 45 7.5k
J. Guillermo Paez 5372 3530 4680 9 8.5k
Paula Herman 5435 3417 4669 13 8.2k

All Works

Loading papers...

Rankless by CCL
2026